Vanguard Global Advisers
CLRB icon

Vanguard Global Advisers’s Cellectar Biosciences CLRB Stock Holding History

Vanguard Global Advisers’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-563
Closed -$1.43K – 3661
2026
Q1 		$1.43K Buy
+563
New +$1.82K ﹤0.01% 3629

Other funds holding CLRB

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Vanguard Global Advisers's CLRB Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Cellectar Biosciences (CLRB) in Q2 2026, closing a stake of 563 shares — an estimated $1.43K sold.

Vanguard Global Advisers first reported a position in CLRB in Q1 2026 and held it in 1 quarter. The position peaked at $1.43K in Q1 2026. 27 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Vanguard Global Advisers reported no remaining Cellectar Biosciences position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 563 Cellectar Biosciences shares in Q2 2026, an estimated $1.43K.
  • Vanguard Global Advisers first reported a position in Cellectar Biosciences in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's Cellectar Biosciences position peaked at $1.43K in Q1 2026.
  • 27 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.